It is suggested that the application of PARP inhibitors with PD-L1 inhibitors requires rigorous biomarker guidance, including BRCA1/2 mutations, PD-L1 expression levels in tumor tissues, tumor genomic microsatellite stability (MSS/MSI), and mutational load (TMB) assessment. This evidence concerns the gene BRCA1 and neoplasm.